Introduction
Leading pharmaceutical research announced a novel antibiotic, Foviscu® (WCK 4282), matched meropenem in Phase 3 trials for complicated urinary tract infections and ESBL-producing bacterial infections.
Also Read: AXISCADES Technologies gains 5% after landing $1 Mn hyperscaler deal via Mistral Solutions
Share price movement of Wockhardt
On January 27, 2026, Wockhardt Ltd opened at ₹1,374.05, up 2.06% from its previous close of ₹1,345.90. The stock reached a high of ₹1,407.35 (4.50%) and a low of ₹1,349.10. By 10:26 AM, it traded at ₹1,377.45, a 2.34% increase, with a market cap of ₹22,381.57 crore.
Wockhardt’s Foviscu® Matches Meropenem in Phase 3 Trial
Wockhardt announced that its intravenous antibiotic Foviscu® (WCK 4282) successfully met primary endpoints in a Phase 3 trial for complicated urinary tract infections and acute pyelonephritis.
The study compared Foviscu® with meropenem in 263 Phase 3 patients. Foviscu® achieved a clinical cure rate of 93.23% versus 92.31% for meropenem, demonstrating therapeutic equivalence and a similar safety profile.
Foviscu® targets Gram-negative bacteria, including ESBL-producing pathogens. It offers a potential alternative to carbapenems, helping reduce resistance. The program enrolled 323 patients across Phase 2 and Phase 3 combined.
Stock performance of Wockhardt for Period of 1 week, 6 months, and 1 year
Wockhardt Ltd declined 1.77% over the past week, fell 18.9% in the past 6 months, and gained 5.98% over the past 1 year.
Also Read: IRB Infra Devs trades in green as ₹9,270 Cr TOT-17 project begins toll collection
Shareholding pattern of Wockhardt
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 49.10% | 49.10% | 49.10% |
| FII | 7.00% | 7.10% | 7.30% |
| DII | 10.60% | 11.00% | 11.00% |
| Public | 33% | 32.80% | 32.60% |
About Wockhardt
Wockhardt Ltd (NSE: WOCKPHARMA) is a global pharmaceutical and biotechnology company manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products including creams and ointments.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Wockhardt Ltd share price rising today?
A: Wockhardt Ltd announced that its intravenous antibiotic Foviscu® (WCK 4282) successfully met primary endpoints in a Phase 3 trial for cUTI and pyelonephritis.
Q: What is Wockhardt Ltd’s main business focus?
A: Wockhardt Ltd focuses on pharmaceuticals and biotechnology, producing finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products.
Q: What is the 52-week high and low of Wockhardt Ltd stock?
A: Wockhardt Ltd stock has a 52-week high of ₹1,870.00 and a 52-week low of ₹1,109.60.
